Aimmune Therapeutics Stock News

Aimmune recently launched their peanut allergy therapy, Palforzia. I discuss my views about this innovative therapy. I believe the coronavirus crash has finally

Aimmune Therapeutics received FDA approval for its Palforzia, so AIMT stock will still be one of the best stocks in 2020.

Amalgamated Bank acquired a new stake in shares of Aimmune Therapeutics Inc (NASDAQ:AIMT) during the 4th quarter, Holdings Channel reports. The fund acquired 8,438 shares of the biotechnology company�

Great West Life Assurance Co. Can purchased a new position in shares of Aimmune Therapeutics Inc (NASDAQ:AIMT) in the fourth quarter, according to the company in its most recent Form 13F filing with t

Global Allergy Immunotherapies Market 2020-2024 The analyst has been monitoring the global allergy immunotherapies market and it is poised to grow by USD 626.77 mn during 2020-2024, progressing at a C

Wall Street brokerages expect that Aimmune Therapeutics Inc (NASDAQ:AIMT) will report $1.79 million in sales for the current quarter, Zacks reports. Six analysts have provided estimates for Aimmune Th

Brinker Capital Inc. lifted its holdings in Aimmune Therapeutics Inc (NASDAQ:AIMT) by 62.7% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC)

Aimmune Therapeutics Inc (NASDAQ:AIMT) was the target of a significant decline in short interest in the month of March. As of March 13th, there was short interest totalling 14,208,700 shares, a declin

The allergy immunotherapies market size has the potential to grow by USD 626.77 million during 2020-2024

Finding and enrolling patients for clinical trials is always challenging. The coronavirus pandemic has made it nearly impossible. Fallout from the spread

Aimmune Therapeutics Inc. is navigating a host of new challenges as it launches Palforzia, the first peanut allergy immunotherapy to be approved by the US

Aimmune Therapeutics Inc (NASDAQ:AIMT) shares rose 8.9% during mid-day trading on Monday . The stock traded as high as $12.62 and last traded at $12.53, approximately 2,564,538 shares traded hands dur

It is not uncommon to see companies perform well in the years after insiders buy shares. On the other hand, we'd be...

Potential Aimmune Therapeutics, Inc. (NASDAQ:AIMT) shareholders may wish to note that the Independent Director...